TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03127189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Rilpivirine 25 mg immediate release oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Rilpivirine 25 mg immediate release oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Rilpivirine 25 mg immediate release oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Rilpivirine 25 mg immediate release oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Rilpivirine 25 mg immediate release oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Long-acting Parenteral Formulation
Description: RPV LA 600 mg extended-release suspension for IM injection.
Study: NCT00264069

Intervention type: DRUG
Intervention: antidepressants
Description: as prescribed
Study: NCT05126667

Intervention type: PROCEDURE
Intervention: Breast-conserving surgery
Description: Breast conserving surgery plus whole breast irradiation

Intervention type: PROCEDURE
Intervention: Mastectomy
Description: Breast mastectomy
Study: NCT03127189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Long-acting Parenteral Formulation
Description: RPV LA 600 mg extended-release suspension for IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Long-acting Parenteral Formulation
Description: RPV LA 600 mg extended-release suspension for IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Long-acting Parenteral Formulation
Description: RPV LA 600 mg extended-release suspension for IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Long-acting Parenteral Formulation
Description: RPV LA 600 mg extended-release suspension for IM injection.
Study: NCT02558361

Intervention type: DRUG
Group type: OTHER
Intervention: Treatment with Apremilast
Description: Standard dosing with apremilast (Otezla) will be used. \[30mg po BID after initial titration\]
Study: NCT04771338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-JIT/KF-STRIDE
Description: Treatment group will receive 12 sessions of job interview training protocol.
Study: NCT03679195

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NO Ultra
Description: 6-week supplementation period with 764 mg/day of cranberry and grape seed extracts (containing polyphenols) and 2 g/day of L-citrulline Participants will have to take daily 2 NO Ultra capsules (containing 382 mg cranberry and grape seed extracts / 1 g L-citrulline) between breakfast and lunch and 2 other NO Ultra capsules between lunch and dinner.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6-week supplementation period with placebo capsules (the active ingredients will be replaced by cellulose)~Participants will have to take 2 capsules of cellulose between breakfast and lunch and 2 capsules between lunch and dinner to match the number of capsules ingested daily by the NO Ultra group.
Study: NCT01473472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: 2 tablets of truvada within 24 hours before first sexual relations, then 1 tablet of Truvada during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of Truvada approximately 24 hours later

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets of placebo within 24 hours before first sexual relations, then 1 tablet of placebo every 24 hours during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of placebo approximatively 24 hours later
Study: NCT00401102

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interpersonal Psychotherapy for Depressed Adolescents
Description: Open clinical trial of IPT-ASI for depressed and self-injuring adolescents, 12-18 years. Goal is to assess feasibility of using IPT-A protocol for teens with co-morbid depression and self-injury. All eligible participants receive 12 weeks of individual IPT-ASI with optional monthly booster sessions. IPT-ASI is a psychosocial intervention that focuses on the importance of interpersonal relationships in relation to psychological functioning. The first phase (4 weeks) includes a review of depression and self-injury symptoms, psycho-education about depression and self-injury, and a detailed assessment of the patient's important interpersonal relationships. The middle phase (weeks 5-9) involves interpersonal skill building, including communication skills, affect identification and expression, problem solving. The final phase ( weeks 10-12) involves review of skills, generalization of skills to other relationships, termination.
Study: NCT00032344

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colonoscopy
Description: Phase I - Cross-sectional; Phase II - 5 year follow-up; Phase III - 10 year follow-up
Study: NCT02811757

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tenotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tenodesis
Study: NCT02978053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright light
Description: Bright light for 30 minutes during night shifts (between 2 AM and 3 AM the first night, between 3 AM and 4 AM the second night, between 4 AM and 5 AM the third night).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Red light
Description: Red light for 30 minutes during night shifts (between 2 AM and 3 AM the first night, between 3 AM and 4 AM the second night, between 4 AM and 5 AM the third night).
Study: NCT02626858

Intervention type: DEVICE
Group type: OTHER
Intervention: extra treatment planning CT-scan
Description: Beside the standard post-operative CT-scan, an extra pre-operative CT-scan is performed.
Study: NCT02917941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone Tablets
Study: NCT00105586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Participants will either take 10 to 20 mg of escitalopram or placebo. Participants who wish to participate in the open-label extension receive an additional 12 weeks of escitalopram.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Participants will either take 10 to 20 mg of escitalopram or placebo. Participants who wish to participate in the open-label extension receive an additional 12 weeks of escitalopram.
Study: NCT06201221

Intervention type: PROCEDURE
Intervention: single-port laparoscopy surgery
Description: The two groups underwent different surgical procedures.

Intervention type: PROCEDURE
Intervention: multiport laparoscopy surgery
Description: The two groups underwent different surgical procedures.
Study: NCT04065217

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Diode laser 980-nm
Description: Before starting the laser session, cosmetics or makeup were removed and the skin was cleaned. The area was anesthetized by the application of as EMLA lotion (lidocaine 2.5% + prilocaine 2.5%) \[ONLY MEDICAL; CAT No. R331/72394/P001\] 20 minutes before the session. During the procedure, the laser probe was held perpendicular to the lesion and a guide beam was used to direct the application. The patient wore protective eye goggles \[CE; DIR 8001100L4\]. After the session, cool air was applied to the whole region. Each patient received a maximum of six sessions, delivered at two-week intervals. Patients reported itchiness and erythema during the session.
Study: NCT00675415

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Capnography
Description: Capnography: Passive measurement of carbon dioxide via a special bite block which allows graphic assessment of the subject's respiratory activity
Study: NCT01642082

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dalantercept
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01351025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: 10 mg daily for 4 weeks, if no symptoms or lab findings suggestive of atorvastatin toxicity, dose increase to 20 mg daily from week 4- week 20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Starting at week 24, 10 mg daily for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, 20 mg daily from week 28- week 44.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for atorvastin
Description: One tablet once daily for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, then increase the dose to two tablets once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for atorvastin
Description: One tablet once daily for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, then increase the dose to two tablets once daily.
Study: NCT00615134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfuvirtide [Fuzeon]
Description: 90mg sc bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized background ARV therapy
Description: As prescribed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimized background ARV therapy
Description: As prescribed
Study: NCT02172703

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive ICP measurement device
Description: The non-invasive ICP measurement device used in this study has been developed in the Telematic Science Laboratory at the Kaunas University of Technology, Lithuania.~The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA).
Study: NCT04379037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: Transcutaneous vagus nerve stimulation involves stimulating the auricular branch of the vagus nerve with a imperceptible electrical current within the concha of the ear.
Study: NCT04182880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL-01
Description: CPL-01 will be administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered
Study: NCT03522077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RadAR EasyCLik plus ®-STF hemostatic pad
Description: Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot in conjunction with the RadAR EasyCLik compression device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TR BAND® Compression device plus ®-STF hemostatic pad
Description: Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot in conjunction with the TR BAND® compression device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SoftSeal®-STF hemostatic pad
Description: Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VascBand™ Hemostat
Description: The VascBand™ Hemostat is an FDA-approved compression device designed to assist hemostasis of arterial, venous and hemodialysis percutaneous access sites.
Study: NCT02696902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3902
Description: Participants will receive a single IV dose of MEDI3902 500 mg and 1500 mg in MEDI3902 500 mg arm and MEDI3902 1500 mg arm, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3902
Description: Participants will receive a single IV dose of MEDI3902 500 mg and 1500 mg in MEDI3902 500 mg arm and MEDI3902 1500 mg arm, respectively.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single IV dose of placebo matched to MEDI3902.
Study: NCT02310451

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood test
Description: blood test to J0-M3-M6-M12
Study: NCT03373864

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral spinal anesthesia
Description: Unilateral spinal anesthesia with hypobaric local anesthesia allowing a lateralized anesthesia of the fractured limb.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: General anesthesia following the latest recommendations for elderly patients (SFAR 2017)
Study: NCT03646630

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block
Description: Posterior or QL block type 2 , a bolus of 0.5 ml/Kg bupivacaine 0.25%

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Block
Description: caudal block with 1 ml/kg of bupivacaine 0.25%.
Study: NCT03555825

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hocoma ArmeoSpring
Description: A spring-loaded upper extremity exoskeleton with 3 joints and 6 degrees of freedom. Participants use the more affected upper extremity to control and engage in therapeutic games.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hocoma ArmeoSpring
Description: A spring-loaded upper extremity exoskeleton with 3 joints and 6 degrees of freedom. Participants use the more affected upper extremity to control and engage in therapeutic games.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hocoma ArmeoSpring
Description: A spring-loaded upper extremity exoskeleton with 3 joints and 6 degrees of freedom. Participants use the more affected upper extremity to control and engage in therapeutic games.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hocoma ArmeoSpring
Description: A spring-loaded upper extremity exoskeleton with 3 joints and 6 degrees of freedom. Participants use the more affected upper extremity to control and engage in therapeutic games.
Study: NCT04337086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T4k Appliance
Description: The pre-fabricated, hard, polyurethane, pink T4K™ (Myo functional research Co., Australia) was used in the study. It consisted of: facial bows, lingual bows / tongue guard, lingual tag / tongue tag, dental channels with a pre-determined bite position and a lip bumper. In the first week, the patients were instructed to gradually increase the wearing time of the appliance during the daytime. By the second week, the patients were instructed to wear the appliance achieving at least 8 hours during sleeping. The Trainer usually needs no adjustments. The patients were asked to place it themselves inside their mouths. The distal ends of the appliance were trimmed 2-3 mm with an acrylic bur on a straight hand piece if they were too long or the patient could not keep his lips together. By the end of the first 4 weeks, the patients were wearing the appliances minimum of 1 hour during the day plus the overnight wear following the manufacturer's instructions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin block appliance
Description: The twin block was used, and instructions were given to wear the appliance nearly full-time. Selective sequential inter-occlusal trimming was done monthly after the 2nd month in the occlusal surface of the maxillary bite blocks to clear over the mandibular molars allowing their eruption in a more favourable mesial direction and to increase the vertical dimension. Trimming was done in the fitting surface over the maxillary and mandibular premolars whenever needed to allow their full eruption and to level the occlusal plane
Study: NCT03579264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Viva Plan
Description: Use of the online platform, My Viva Plan, to support health and wellness.
Study: NCT02456805

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant Formula 1
Description: Feed ab libitum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula 2
Description: Feed ab libitum
Study: NCT02820584

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSC-loaded autologous dendritic cells
Study: NCT01414426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: biopsy
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01857622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b 15mg
Description: oral DU-176b 15mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b 30mg
Description: oral DU-176b 30mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b 60mg
Description: oral DU-176b 60mg once daily
Study: NCT00874432

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: angiotensin converting enzyme inhibitor
Description: Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: angiotensin converting enzyme inhibitor
Description: Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisinopril
Description: 1 x 40 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisinopril
Description: 1 x 40 mg per day
Study: NCT03412968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polysulfone Filter
Description: The intervention for this group consisted using a Polysulfone filter in order to hemofiltration in the procedure involving Cardiopulmonary Bypass (CPB).The perfusionist's role is essential during the procedure, as they control both Cardiac Output (CO) and gas exchange, depending on their action, will affect blood lactate levels.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure/ Surgery: without Polysulfone Filter
Description: In this group, no intervention is performed during the procedure involving Cardiopulmonary Bypass (CPB)
Study: NCT03200756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary Group
Description: The sedentary group undergoes a behavioral intervention to reduce sedentary behavior which includes a patient centered approach with monitoring and goal setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Group
Description: The Active Comparative group undergoes a standard clinical approach to increase exercise which is patient centered with monitoring and goal setting.
Study: NCT01329809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Description: intratumoral or intravenous dosage: 10e9 pfu Intravenous: administered over 60 minutes Intratumoral: direct injection into a single liver lesion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Description: intratumoral or intravenous dosage: 10e9 pfu Intravenous: administered over 60 minutes Intratumoral: direct injection into a single liver lesion
Study: NCT02177903

Intervention type: DEVICE
Group type: OTHER
Intervention: Bair Paws Patient Adjustable Warming System
Description: Bair Paws system uses forced-air warming. This system will be used for patients randomized to active pre-warming.

Intervention type: DEVICE
Group type: OTHER
Intervention: Bair Paws Patient Adjustable Warming System
Description: Bair Paws system uses forced-air warming. This system will be used for patients randomized to active pre-warming.
Study: NCT04471233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia including pregabalin
Description: Standardized protocol for our institution with multiple medications used for pain (NSAIDs, opioids, dexamethasone) and non-narcotic spinal. Patient will be provided with an preoperative pregabalin dose and will continue medication two weeks postoperatively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal analgesia not including pregabalin
Description: Standardized protocol for our institution with multiple medications used for pain (NSAIDs, opioids, dexamethasone) and non-narcotic spinal.
Study: NCT02273375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03482297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: automated abdominal binder
Description: The binder automatically inflates every time the participant stands up to apply a compression level of about 40 mmHg. Participants will wear the device throughout the active/sham study day.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham binder
Description: The binder automatically inflates every time the participant stands up to apply a compression level of about 5 mmHg. Participants will wear the device throughout the active/sham study day.
Study: NCT00964457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: cetuximab 500mg per meter square every second week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: cetuximab 500mg per meter square every second week
Study: NCT02076074

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: accelerated partial breast irradiation
Description: Undergo HG-PBI
Study: NCT02873026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Following the repair of the open globe eye trauma, the use of Triamcinolone Acetonide will be investigated